ArticleDrug and alcohol review2026
Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study.
Article in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionThis paper aimed to determine the prevalence, demographic correlates and co-occurring substance use patterns of hallucinogen microdosing among young adults in the United States.
methodsDesign: Cross-sectional analysis of data from a nationally-representative cohort study collected in 2022-2023.
settingUnited States.
participantsSample of 3094 young adults aged 19-30 years in the Monitoring the Future panel study. MEASUREMENTS: Self-reported past-year hallucinogen use and at least one past-year incident of microdosing, demographic characteristics (age, sex, race/ethnicity, college attendance, parental education) and other substance use (alcohol, cannabis, nicotine, other drugs).
resultsPast-year hallucinogen use was reported by 9.5% (SE = 0.68) of young adults, with microdosing reported by 6.8% (SE = 0.61). Among those who used hallucinogens, 73.1% (SE = 3.6) engaged in microdosing. Individuals who reported microdosing demonstrated substantially higher rates of other substance use, with odds ratios ranging from 2.53 (95% CI 1.43-4.47) for past-month cigarette use to 37.73 (95% CI 19.72-72.21) for 3+ occasions of past-year cannabis use. Among those who microdosed, 72.4% reported 10+ occasions of past-year alcohol use and 85.8% reported 3+ occasions of past-year cannabis use. There were few significant demographic differences in microdosing, though Black respondents were less likely (OR = 0.43, 95% CI 0.21-0.90) to microdose compared with White respondents. DISCUSSION AND
conclusionsApproximately 1 in 15 US young adults reported microdosing hallucinogens, with strong associations between microdosing and other substance use. Despite growing interest in potential therapeutic applications of microdosing, the context in which microdosing typically occurs, including patterns of other drug and alcohol use, raises concerns and warrants focused prevention efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.